A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

Also called NCT07421232

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 156 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07421232
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07421232. Randomized; single masking; primary purpose treatment. Start 2024-12-03 (actual); primary completion 2025-08-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Condition
Hypercholesterolemia and Mixed Hyperlipidemia
Intervention (Drug)
SYH2053/placebo injection
Intervention (Drug)
Inclisiran (Leqvio®) 300mg
Lead sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07421232
Content hash
8e8db29e8bf35f30aa10843a1b4c33b9230f552e33e695b7593766555bbffe32